AKTXAkari TherapeuticsAKTX info
$3.32info1.53%24h
Global rank30355
Market cap$18.77M
Change 7d-12.63%
YTD Performance7.79%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Akari Therapeutics (AKTX) Stock Overview

    Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

    AKTX Stock Information

    Symbol
    AKTX
    Address
    75/76 Wimpole StreetLondon, W1G 9RTUnited Kingdom
    Founded
    -
    Trading hours
    -
    Website
    https://www.akaritx.com
    Country
    🇬🇧 United Kingdom
    Phone Number
    44 20 8004 0270

    Akari Therapeutics (AKTX) Price Chart

    -
    Value:-

    Akari Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $3.32
    N/A
    Market Cap
    $18.77M
    N/A
    Shares Outstanding
    5.65M
    N/A
    Employees
    15.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org